Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123857
Published online Nov 15, 2026. doi: 10.4251/wjgo.123857
Published online Nov 15, 2026. doi: 10.4251/wjgo.123857
Table 2 Side effects associated with two groups treatment, n (%)
| Variables | Total (n = 181) | FOLFOX (n = 68) | P-SOX (n = 113) | Statistic | P value |
| Nausea and vomiting | 0.123 | ||||
| 0 | 42 (23.20) | 13 (19.12) | 29 (25.66) | ||
| 1 | 101 (55.80) | 35 (51.47) | 66 (58.41) | ||
| 2 | 34 (18.78) | 17 (25.00) | 17 (15.04) | ||
| 3 | 4 (2.21) | 3 (4.41) | 1 (0.88) | ||
| Liver toxicity | - | 0.165 | |||
| 0 | 151 (83.43) | 58 (85.29) | 93 (82.30) | ||
| 1 | 26 (14.36) | 7 (10.29) | 19 (16.81) | ||
| 2 | 4 (2.21) | 3 (4.41) | 1 (0.88) | ||
| Alopecia | χ2 = 3.03 | 0.220 | |||
| 0 | 94 (51.93) | 36 (52.94) | 58 (51.33) | ||
| 1 | 74 (40.88) | 30 (44.12) | 44 (38.94) | ||
| 2 | 13 (7.18) | 2 (2.94) | 11 (9.73) | ||
| Peripheral sensory neuropathy | 0.790 | ||||
| 0 | 91 (50.28) | 35 (51.47) | 56 (49.56) | ||
| 1 | 72 (39.78) | 26 (38.24) | 46 (40.71) | ||
| 2 | 16 (8.84) | 7 (10.29) | 9 (7.96) | ||
| 3 | 2 (1.10) | 0 (0.00) | 2 (1.77) | ||
| Fewer neutrophils | 0.387 | ||||
| 0 | 132 (72.93) | 45 (66.18) | 87 (76.99) | ||
| 1 | 34 (18.78) | 16 (23.53) | 18 (15.93) | ||
| 2 | 7 (3.87) | 4 (5.88) | 3 (2.65) | ||
| 3 | 7 (3.87) | 3 (4.41) | 4 (3.54) | ||
| 4 | 1 (0.55) | 0 (0.00) | 1 (0.88) | ||
| Fewer white blood cells | 0.027 | ||||
| 0 | 102 (56.35) | 43 (63.24) | 59 (52.21) | ||
| 1 | 54 (29.83) | 14 (20.59) | 40 (35.40) | ||
| 2 | 16 (8.84) | 8 (11.76) | 8 (7.08) | ||
| 3 | 5 (2.76) | 0 (0.00) | 5 (4.42) | ||
| 4 | 4 (2.21) | 3 (4.41) | 1 (0.88) | ||
| Fewer platelets | 0.521 | ||||
| 0 | 133 (73.48) | 52 (76.47) | 81 (71.68) | ||
| 1 | 31 (17.13) | 10 (14.71) | 21 (18.58) | ||
| 2 | 12 (6.63) | 3 (4.41) | 9 (7.96) | ||
| 3 | 5 (2.76) | 3 (4.41) | 2 (1.77) | ||
| Anemia | χ2 = 2.64 | 0.450 | |||
| 0 | 94 (51.93) | 36 (52.94) | 58 (51.33) | ||
| 1 | 62 (34.25) | 21 (30.88) | 41 (36.28) | ||
| 2 | 15 (8.29) | 5 (7.35) | 10 (8.85) | ||
| 3 | 10 (5.52) | 6 (8.82) | 4 (3.54) |
- Citation: Ji BY, Qi LL, Fan DY, Zhang Y, He L, Zhang K, Liu ZB. Nab-paclitaxel-oxaliplatin-S-1 vs FOLFOX in locally advanced gastric cancer: Efficacy and postoperative disease-free survival prediction. World J Gastrointest Oncol 2026; 18(11): 123857
- URL: https://www.wjgnet.com/1948-5204/full/v18/i11/123857.htm
- DOI: https://dx.doi.org/10.4251/wjgo.123857